What Breast Implants Have Been Recalled?

Several breast implant products have been formally recalled or pulled from the market over the past three decades, but the recall that affected the most people in the United States was Allergan’s Biocell textured breast implants and tissue expanders, voluntarily withdrawn worldwide in July 2019 after the FDA linked them to a rare cancer called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). That recall was not an isolated event. It followed earlier scandals involving fraudulent silicone gel from the French manufacturer Poly Implant Prothèse (PIP), contamination issues with Brazilian-made Silimed devices, and a quieter withdrawal of soybean-oil-filled Trilucent implants in the early 2000s. Each recall had a different cause, and understanding which products were involved, why they were pulled, and what it means for people who still have them requires looking at each case on its own terms.

The Allergan Biocell Recall

On July 24, 2019, the FDA requested the immediate withdrawal of all Allergan Biocell breast implants and tissue expanders. Allergan issued a global recall of these devices the same day.¹ The products had been in the midst of growing international concern about BIA-ALCL, and the FDA ban in the U.S. was preceded by regulatory actions in Europe, Canada, Brazil, and Australia.¹ Biocell implants had a heavily textured surface, and the vast majority of BIA-ALCL cases worldwide were linked to textured devices, with Biocell’s aggressive “macrotexture-plus” surface standing out as the most frequently implicated.

What made the Biocell surface distinctive was its depth and roughness. Breast implant surfaces range from smooth to heavily textured, and researchers have grouped them into categories based on surface area measurements: smooth or nanotextured at one end, microtextured in the middle, and macrotextured or macrotexture-plus at the high end.² Biocell fell into the most aggressive category. Other textured implants with finer surfaces, like the Siltex line, fall into the “microtexture” range and have been associated with far fewer BIA-ALCL cases.³ That distinction matters because the recall targeted Biocell specifically, not all textured implants on the market.

The scale of the recall was enormous. At one major university breast center, letters were sent to 1,256 affected patients. Despite that large number, no cases of BIA-ALCL were detected among them, which reinforced the idea that the disease clusters geographically and remains quite rare even among those with the recalled devices.⁴ That is a reassuring finding for the millions of women worldwide who received Biocell implants, though it doesn’t eliminate the need for awareness and monitoring.

The PIP Scandal

Before the Allergan recall dominated headlines, the biggest breast implant crisis of the modern era came from France. Poly Implant Prothèse (PIP) was a manufacturer whose devices were pulled from the market in March 2010 by the French health products safety agency after an unusually high rate of ruptures was observed clinically.⁵ Subsequent testing confirmed what regulators suspected: PIP had been using silicone of improper quality for both the outer shell and the gel filling. The company had essentially swapped approved medical-grade silicone for cheaper industrial-grade material to save on production costs.

The fallout was international. PIP implants had been distributed widely across Europe, South America, and parts of Asia and the Middle East. As of late 2011, no acute toxicity or mutagenic effects had been confirmed in testing, but 20 cases of malignancies had been reported among PIP implant carriers.⁵ Those numbers were concerning enough that several countries recommended prophylactic removal. PIP implants were never sold in the United States, so American patients were not directly affected, but the scandal reshaped global expectations for implant manufacturing oversight and became a reference point for regulators everywhere.

A study of patients affected by the PIP recall found that quality of life improved after removal, particularly among women who had originally received implants for congenital breast malformations. Among cancer reconstruction patients, quality of life was generally better compared to other groups both before and after removal.⁶ The psychological toll of being told your implants contain fraudulent material is significant, and for many women the anxiety of leaving them in place was worse than undergoing another surgery.

Silimed and Trilucent

In September 2015, the CE certificate covering Silimed medical devices was suspended for three months after the Brazilian company failed to resolve an issue with particulate contamination of its silicone breast implants. Reports by the notified body found particles on several textured implants, including particles described as glass fibers.⁷ The suspension temporarily pulled Silimed products from the European market while the contamination issue was assessed. While the contamination did not lead to a wave of reported injuries comparable to the PIP or Allergan situations, it was a sharp reminder that manufacturing quality control in breast implants is not something patients can take for granted.

Going further back, Trilucent implants occupied a strange chapter in implant history. These devices used soybean oil as a filler instead of silicone, marketed in the 1990s partly as a “natural” alternative that would be radiolucent on mammography. They were voluntarily withdrawn in 1999 after concerns emerged about the oil degrading inside the body. A chemical analysis of 51 consecutively removed Trilucent implants found that every single one showed evidence of shell deterioration consistent with lipid absorption and lipid bleed through the shell wall. The implants lost almost two percent of their weight per year on average. Although none had actually ruptured in the body, many had anterior and posterior patch delaminations that made rupture likely over time. Most concerning, the soybean oil in all the explanted devices had undergone peroxidation, producing aldehyde byproducts at millimolar concentrations.⁸ Aldehydes are chemically reactive compounds, and their presence inside a body was not a finding anyone could dismiss. Trilucent implants are no longer manufactured or sold anywhere.

Why Textured Surfaces and BIA-ALCL Are Connected

The Allergan recall raised the obvious question: what is it about textured implants that promotes a rare lymphoma? The answer appears to involve multiple overlapping factors. The likely cause of BIA-ALCL is multifactorial, with current evidence pointing to a combination of chronic infection around textured implants, gram-negative biofilm formation, chronic inflammation, and host genetics. Among the proposed triggers, the bacterial hypothesis has received the most attention. In this model, bacteria form an adherent biofilm on the textured implant surface, which provides a favorable environment for persistent bacterial colonies. That bacterial load then provokes a chronic inflammatory response that, over years, can push immune cells toward malignant transformation in genetically susceptible individuals.⁹

Mechanical friction from the textured surface, silicone shell particulates, and silicone leachables have also been proposed as contributing triggers.⁹ The rougher the surface, the more surface area for biofilm to form and the more mechanical irritation the surrounding tissue experiences. That helps explain why the most heavily textured devices like Biocell were disproportionately represented in BIA-ALCL cases while smoother textures carried far lower risk. It also explains the geographic clustering: different surgical practices, local bacterial environments, and possibly even differences in how the implants were handled at the time of surgery could all affect biofilm formation.

How BIA-ALCL Shows Up

BIA-ALCL typically presents years after the original implant surgery, not weeks or months. In roughly 80 percent of affected women, the disease shows up as a late-developing fluid collection (called a seroma) around the implant. In the remaining cases, it presents as a solid mass with or without an accompanying seroma.¹⁰ The most common thing a patient notices is that one breast gradually swells or feels different, often many years after surgery. Pain is sometimes present but not always.

The good news is that most BIA-ALCL patients present with localized disease, and localized BIA-ALCL carries an excellent prognosis.¹¹ When detected early as a seroma confined to the implant capsule, the standard treatment is surgical removal of the implant along with the intact surrounding capsule, a procedure known as total en-bloc capsulectomy. UK guidelines indicate this procedure is usually curative.¹² Cases that present with a mass rather than just fluid tend to have worse outcomes, with significantly worse progression-free survival in patients with an implant-associated mass.¹³ That makes early detection important.

Ultrasound is the most practical first-line imaging tool for anyone with a concerning symptom. In a study of 44 BIA-ALCL patients who had imaging between 1997 and 2013, ultrasound had 84 percent sensitivity for detecting a fluid collection around the implant, while MRI reached 82 percent. For detecting a solid mass, PET scanning was most sensitive at 64 percent, and ultrasound was only 46 percent.¹³ Since all cases of BIA-ALCL have had a fluid collection at the time of diagnosis, ultrasound may be the most cost-effective initial test when a clinician suspects a problem.¹⁴ If fluid is found, it can be aspirated and tested for abnormal cells, which is how the diagnosis is confirmed.

If You Have Recalled Implants and No Symptoms

The question that haunted hundreds of thousands of women after the Allergan recall was simple: should I have these removed even though I feel fine? The honest answer is that there was, and still is, no strong consensus. A lack of clear published recommendations or scientific data to guide surgeons on managing asymptomatic patients after the recall left many doctors navigating the question case by case. Neither the FDA nor major professional societies issued blanket recommendations for prophylactic removal in asymptomatic patients. Instead, the general guidance has been awareness, ongoing follow-up, and prompt evaluation if any new symptoms develop, particularly unexplained swelling or a lump near the implant.

For some women, that uncertainty was itself intolerable, and they chose removal for peace of mind. Others opted to keep their implants and stay vigilant. Both decisions are medically defensible, and the choice hinges on how a patient weighs a very small but real cancer risk against the costs and recovery of additional surgery. Surgeons who specialize in this area generally encourage patients to be informed partners in that decision rather than passive recipients of a single recommendation.

Breast Implant Illness Beyond the Recalls

Recalls have centered on specific safety failures: fraudulent silicone, cancer risk, contamination. But a broader set of complaints has gathered under the term “breast implant illness” (BII), which describes a constellation of systemic symptoms some patients report after implantation, including fatigue, cognitive problems, joint and muscle pain, dry eyes and mouth, skin changes, and mood disturbance.¹⁵ BII has not triggered a formal product recall from any manufacturer, but it has deeply influenced the regulatory conversation around implants.

Proposed mechanisms for BII include chronic foreign-body inflammation, silicone gel bleed and particulate migration, immune activation and autoantibody formation, and bacterial biofilms on the implant surface.¹⁵ No validated diagnostic biomarker exists yet, and causality remains controversial, which is part of why no recall has been issued. A meta-analysis of five studies estimated that about 24 percent of patients identified as having BII tested positive for antinuclear antibodies, a marker sometimes associated with autoimmune activity.¹⁶ That prevalence is higher than what you would expect in the general population but not high enough to be diagnostic on its own, since antinuclear antibodies can be found in healthy people too.

The debate over BII is separate from the recall story, but the two conversations overlap in practice. Many women who sought explantation after the Allergan recall also reported systemic symptoms they attributed to their implants, and those symptoms sometimes improved after removal. Whether that improvement was related to removal of the implant itself or to resolution of the anxiety and uncertainty surrounding it, or both, remains an open question.

How the Regulatory Landscape Changed

The cascade of recalls and safety concerns from PIP through Allergan reshaped how breast implants are regulated, particularly in the United States. In October 2021, the FDA announced a new requirement: clinicians must review a manufacturer-produced “Patient Decision Checklist” with all women considering breast implants. Patients must initial under each of the mandatory talking points, and both the patient and the surgeon must sign the document. The FDA restricted the sale and distribution of breast implants to providers and facilities that comply with this checklist requirement.¹⁷ This was a significant departure from the FDA’s usual posture on surgical informed consent, which historically left the specific content of the conversation to the physician’s discretion.

The checklist covers topics including the risk of BIA-ALCL, the possibility of BII symptoms, the likelihood of needing future surgeries, and rupture rates. It does not replace the surgeon’s own informed consent discussion but adds a standardized layer on top of it. Breast implant manufacturers communicated with plastic surgeons in 2022 about using the checklist as a condition for the sale of implants.¹⁸ In theory, this means a surgeon who refuses to use the checklist cannot purchase implants from any FDA-approved manufacturer. In practice, enforcement and standardization remain works in progress.¹⁹

Alternatives After Explantation

For women who have recalled implants removed, or who choose explantation for any reason, the question of what comes next is deeply personal. Some opt for new implants with a different surface profile or from a different manufacturer. Others decide they are done with implants entirely. For that second group, autologous fat grafting has emerged as a viable alternative, at least for modest changes in breast volume.

Fat grafting involves harvesting fat from another part of the body and injecting it into the breast. Compared to implants, this approach has been found to produce more natural-looking results and has also shown benefits for patients with chest wall asymmetries or unilateral underdevelopment.²⁰ A comparative study found that fat grafting provided patient satisfaction comparable to implants while offering better physical well-being, though it works best for patients seeking moderate augmentation who have enough donor fat available.²¹ It is not a replacement for implants in every scenario. Women who want a significant increase in size, or who lack sufficient body fat for harvesting, will find fat grafting limited. And the procedure typically requires multiple sessions to achieve a stable result, which adds time and cost.

For breast cancer reconstruction patients specifically, the picture is more complex. Reconstruction after mastectomy often requires tissue flap procedures or implant-based approaches that fat grafting alone cannot replicate. These patients navigate the recall landscape with the additional burden of having fewer practical alternatives and a stronger medical justification for the original implants. Their conversations with surgeons tend to focus not on whether to have an implant at all, but on which device and which surface carry the most favorable risk profile going forward.